Cautious Hold Rating on Fulcrum Therapeutics Amid Uncertain Prospects and Strategic Shifts
Andrew Fein, an analyst from H.C. Wainwright, reiterated the Hold rating on Fulcrum Therapeutics (FULC – Research Report). The associated ...
Promising Outlook for Astria Therapeutics: Strong Financials and Key Program Advancements Support Buy Rating
Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Astria Therapeutics (ATXS – Research Report), retaining the price ...
Aspira Women's Health Inc. (AWH) Q3 2024 Earnings Call Transcript
Good morning, ladies and gentlemen and welcome to Aspira Women's Health Incorporated Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. Following ...
Dynavax Technologies: What The Stock Buyback Means, What It Doesn't
Dynavax Technologies Corporation's flagship product, Heplisav-B, continues to increase market share consistently in a growing ...
Q3 2024 Acurx Pharmaceuticals Inc Earnings Call
Robert Deluccia; Executive Chairman, Co-Founder, Managing Partner, Executive Director; Acurx Pharmaceuticals Inc Laura Molloy; Analyst; Alliance resource partners ...
BBC14h
Open Book
Programme looking at new fiction and non-fiction books, talking to authors and publishers and unearthing lost classics ...